Chi‐Chung Li

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar et al. · The Lancet Oncology · 2022 · 436 citations · Full text

Medicine, Clinical Sciences, Oncology +16

Modeling Ophthalmic Drug Delivery by Soaked Contact Lenses

Chi‐Chung Li, Anuj Chauhan · Industrial & Engineering Chemistry Research · 2006 · 230 citations

Pharmacy, Ophthalmology, Pharmacology +17

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Stephen J. Schuster, Nancy L. Bartlett, Sarit Assouline et al. · Blood · 2019 · 182 citations

Medicine, Immunology, Oncology +17

TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution

Liang‐In Lin, M-H Tseng, MC Liu et al. · Blood Cancer Journal · 2015 · 162 citations · Full text

Medicine, Hematology, Oncology +16

Dispersion of DMPC Liposomes in Contact Lenses for Ophthalmic Drug Delivery

Derya Gulsen, Chi‐Chung Li, Anuj Chauhan · Current Eye Research · 2005 · 157 citations

Pharmacy, Ophthalmology, Pharmacology +17